Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway

Endocrine-Related Cancer

Volumn 22, Issue 4, 2015, Pages 577-591

  Yuan, Lingqin ^a,b   Sheng, Xiugui ^a   Willson, Adam K ^b   Roque, Dario R ^b   Stine, Jessica E ^b   Guo, Hui ^a,b   Jones, Hannah M ^b   Zhou, Chunxiao ^b   Bae Jump, Victoria L ^b  

^a UNIVERSITY OF JINAN   (China)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Glutamate dehydrogenase; Glutaminase; mTOR S6; Ovarian cancer; siRNA

Indexed keywords

ENDOPLASMIC RETICULUM STRESS PROTEIN; GLUCOSE; GLUTAMATE DEHYDROGENASE; GLUTAMINASE; GLUTAMINE; HEAT SHOCK PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; S6 KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; LACTIC ACID; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG METABOLISM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL CYCLE; CELL TRANSFORMATION; DRUG EFFECTS; FEMALE; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GLUCOSE; GLUTAMINE; HUMANS; LACTIC ACID; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; REACTIVE OXYGEN SPECIES; RIBOSOMAL PROTEIN S6 KINASES; TOR SERINE-THREONINE KINASES;

EID: 84940108436     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0192     Document Type: Article

References (56)

1. Ainmhire EÓ, Quartuccio SM, Cheng W, Ahmed RA, King SM & Burdette JE 2014 Mutation or loss of p53 differentially modifies TGFb action in ovarian cancer. PLoS ONE 9 e89553. (doi:10.1371/journal.pone.0089553)
2. Antico Arciuch VG, Russo MA, Kang KS & Di Cristofano A 2013 Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Research 73 5459-5472. (doi:10.1158/0008-5472.CAN-13-1429)
3. Ayyagari VN & Brard L 2014 Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer 14 61. (doi:10.1186/1471-2407-14-61)
4. Bayley JP & Devilee P 2012 The Warburg effect in 2012. Current Opinion in Oncology 24 62-67. (doi:10.1097/CCO.0b013e32834deb9e)
5. Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Colon M, Dodson CS, Gilbert SA, Greshock J, Jing J et al. 2013 Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer & Metabolism 1 19. (doi:10.1186/2049-3002-1-19)
6. Boukhettala N, Claeyssens S, Bensifi M, Maurer B, Abed J, Lavoinne A, Dechelotte P & Coeffier M 2012 Effects of essential amino acids or glutamine deprivation on intestinal permeability and protein synthesis in HCT-8 cells: involvement of GCN2 and mTOR pathways. Amino Acids 42 375-383. (doi:10.1007/s00726-010-0814-x)
7. Collins CL, Wasa M, Souba WW & Abcouwer SF 1998 Determinants of glutamine dependence and utilization by normal and tumor-derived breast cell lines. Journal of Cellular Physiology 176 166-178. (doi:10.1002/(SICI)1097-4652(199807)176:1〈166::AID-JCP18〉3.0.CO;2-5)
8. Crespo I, San-Miguel B, Prause C, Marroni N, Cuevas MJ, Gonzalez-Gallego J & Tunon MJ 2012 Glutamine treatment attenuates endoplasmic reticulum stress and apoptosis in TNBS-induced colitis. PLoS ONE 7 e50407. (doi:10.1371/journal.pone.0050407)
9. Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T et al. 2013 The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153 840-854. (doi:10.1016/j.cell.2013.04.023)
10. Dang CV 2010 Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle 9 3884-3886. (doi:10.4161/cc.9.19.13302)
11. DeBerardinis RJ & Cheng T 2010 Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 29 313-324. (doi:10.1038/onc.2009.358)
12. Fu YM, Yu ZX, Li YQ, Ge X, Sanchez PJ, Fu X & Meadows GG 2003 Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutrition and Cancer 45 60-73. (doi:10.1207/S15327914NC4501-8)
13. Fu YM, Zhang H, Ding M, Li YQ, Fu X, Yu ZX & Meadows GG 2004 Specific amino acid restriction inhibits attachment and spreading of human melanoma via modulation of the integrin/focal adhesion kinase pathway and actin cytoskeleton remodeling. Clinical & Experimental Metastasis 21 587-598. (doi:10.1007/s10585-004-5515-y)
14. Fu YM, Zhang H, Ding M, Li YQ, Fu X, Yu ZX &Meadows GG 2006 Selective amino acid restriction targets mitochondria to induce apoptosis of androgen-independent prostate cancer cells. Journal of Cellular Physiology 209 522-534. (doi:10.1002/jcp.20766)
15. Fu YM, Yu ZX, Lin H, Fu X & Meadows GG 2008 Selective amino acid restriction differentially affects the motility and directionality of DU145 and PC3 prostate cancer cells. Journal of Cellular Physiology 217 184-193. (doi:10.1002/jcp.21490)
16. Fu YM, Lin H, Liu X, Fang W & Meadows GG 2010 Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism. Journal of Cellular Physiology 224 491-500. (doi:10.1002/jcp.22148)
17. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J et al. 2014 Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Molecular Cancer Therapeutics 13 890-901. (doi:10.1158/1535-7163.MCT-13-0870)
18. Hammoudi N, Ahmed KB, Garcia-Prieto C & Huang P 2011 Metabolic alterations in cancer cells and therapeutic implications. Chinese Journal of Cancer 30 508-525. (doi:10.5732/cjc.011.10267)
19. Helmlinger G, Sckell A, Dellian M, Forbes NS & Jain RK 2002 Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clinical Cancer Research 8 1284-1291.
20. Hensley CT, Wasti AT & DeBerardinis RJ 2013 Glutamine and cancer: cell biology, physiology, and clinical opportunities. Journal of Clinical Investigation 123 3678-3684. (doi:10.1172/JCI69600)
21. Hu W, Zhang C, Wu R, Sun Y, Levine A & Feng Z 2010 Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. PNAS 107 7455-7460. (doi:10.1073/pnas.1001006107)
22. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ & Dutta A 2013 Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Molecular Cancer Therapeutics 12 1958-1967. (doi:10.1158/1535-7163.MCT-12-1028)
23. Kaadige MR, Looper RE, Kamalanaadhan S & Ayer DE 2009 Glutaminedependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. PNAS 106 14878-14883. (doi:10.1073/pnas.0901221106)
24. Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Yamamoto E, Fujiwara S, Kawai M, Nagasaka T & Kikkawa F 2012 Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type? International Journal of Gynecological Cancer 22 394-399. (doi:10.1097/IGC.0b013e31823eed2c)
25. Kee HJ & Cheong JH 2014 Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy. BMB Reports 47 158-166. (doi:10.5483/BMBRep.2014.47.3.273)
26. Kim J, Song G, Wu G, Gao H, Johnson GA & Bazer FW 2013 Arginine, leucine, and glutamine stimulate proliferation of porcine trophectoderm cells through the MTOR-RPS6K-RPS6-EIF4EBP1 signal transduction pathway. Biology of Reproduction 88 113. (doi:10.1095/biolreprod.112.105080)
27. Kim DS, Jue SS, Lee SY, Kim YS, Shin SY&KimEC2014 Effects of glutamine on proliferation, migration, and differentiation of human dental pulp cells. Journal of Endodontics 40 1087-1094. (doi:10.1016/j.joen.2013.11.023)
28. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP & Martinez-Outschoorn UE 2011 Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biology & Therapy 12 1085-1097. (doi:10.4161/cbt.12.12.18671)
29. Koochekpour S, Majumdar S, Azabdaftari G, Attwood K, Scioneaux R, Subramani D, Manhardt C, Lorusso GD, Willard SS, Thompson H et al. 2012 Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clinical Cancer Research 18 5888-5901. (doi:10.1158/1078-0432.CCR-12-1308)
30. Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC, Schwenn M, Johnson A, Jones M, Kida M et al. 2012 Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiology, Biomarkers & Prevention 21 1555-1564. (doi:10.1158/1055-9965.EPI-12-0261)
31. Liu X, Fu YM & Meadows GG 2011 Differential effects of specific amino acid restriction on glucose metabolism, reduction/oxidation status and mitochondrial damage in DU145 and PC3 prostate cancer cells. Oncology Letters 2 349-355. (doi:10.3892/ol.2011.237)
32. Mirandola L, M JC, Cobos E, Bernardini G, Jenkins MR, Kast WM & Chiriva-Internati M 2011 Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. International Reviews of Immunology 30 127-137. (doi:10.3109/08830185.2011.572504)
33. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C et al. 2009 Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136 521-534. (doi:10.1016/j.cell.2008.11.044)
34. Phang JM, LiuW& Hancock C 2013 Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics 8 231-236. (doi:10.4161/epi.24042)
35. Qie S, Chu C, Li W, Wang C & Sang N 2014 ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. Journal of Cellular Biochemistry 115 498-509. (doi:10.1002/jcb.24684)
36. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM et al. 2012 ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell 22 631-644. (doi:10.1016/j.ccr.2012.09.021)
37. Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG & Horowitz NS 2013 Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecologic Oncology 129 63-68. (doi:10.1016/j.ygyno.2013.01.009)
38. Rooth C 2013 Ovarian cancer: risk factors, treatment and management. British Journal of Nursing 22 S23-S30. (doi:10.12968/bjon.2013.22. Sup17.S23)
39. Roy S & Maity P 2005 Effect of glutamine analogue-acivicin on tumor induced angiogenesis in Ehrlich ascites carcinoma. Indian Journal of Experimental Biology 43 407-413.
40. Saqcena M, Menon D, Patel D, Mukhopadhyay S, Chow V & Foster DA 2013 Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle. PLoS ONE 8 e74157. (doi:10.1371/journal.pone.0074157)
41. Saqcena M, Mukhopadhyay S, Hosny C, Alhamed A, Chatterjee A & Foster DA 2015 Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. Oncogene 34 2672-2680. (doi:10.1038/onc.2014.207)
42. Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, Kim K & Bae-Jump VL 2014 Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecologic Oncology 134 346-355. (doi:10.1016/j.ygyno.2014.05.015)
43. Shanware NP, Mullen AR, DeBerardinis RJ & Abraham RT 2011 Glutamine: pleiotropic roles in tumor growth and stress resistance. Journal of Molecular Medicine 89 229-236. (doi:10.1007/s00109-011-0731-9)
44. Siegel R, Ma J, Zou Z & Jemal A 2014 Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 64 9-29. (doi:10.3322/caac.21208)
45. Simpson NE, Tryndyak VP, Pogribna M, Beland FA & Pogribny IP 2012 Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics 7 1413-1420. (doi:10.4161/epi.22713)
46. Sung PL, Chang YH, Chao KC, Chuang CM, Task Force on Systematic R & Meta-analysis of Ovarian C 2014 Global distribution pattern of histological subtypes of epithelial ovarian cancer: a database analysis and systematic review. Gynecologic Oncology 133 147-154. (doi:10.1016/j.ygyno.2014.02.016)
47. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y et al. 2010 Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. PNAS 107 7461-7466. (doi:10.1073/pnas.1002459107)
48. Thornthwaite JT & Allen LM 1980 The effect of the glutamine analog, AT-125, on the cell cycle of MCF-7 and BT-20 human breast carcinoma cells using DNA flow cytometry. Research Communications in Chemical Pathology and Pharmacology 29 393-396.
49. Traves PG, de Atauri P, Marin S, Pimentel-Santillana M, Rodriguez-Prados JC, Marin de Mas I, Selivanov VA, Martin-Sanz P, Bosca L & Cascante M 2012 Relevance of the MEK/ERK signaling pathway in the metabolism of activated macrophages: a metabolomic approach. Journal of Immunology 188 1402-1410. (doi:10.4049/jimmunol.1101781)
50. Wang J, Ma X, Jones HM, Chan LL, Song F, Zhang W, Bae-Jump VL & Zhou C 2014 Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. Journal of Translational Medicine 12 226. (doi:10.1186/s12967-014-0226-x)
51. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR & Chandel NS 2010 Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. PNAS 107 8788-8793. (doi:10.1073/pnas.1003428107)
52. Willems L, Jacque N, Jacquel A, Neveux N, Maciel TT, Lambert M, Schmitt A, Poulain L, Green AS, Uzunov M et al. 2013 Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood 122 3521-3532. (doi:10.1182/blood-2013-03-493163)
53. Xie X, Bartholomeusz C, Ahmed AA, Kazansky A, Diao L, Baggerly KA, Hortobagyi GN & Ueno NT 2013 Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubuledestabilizing effect of SCLIP. Molecular Cancer Therapeutics 12 1099-1111. (doi:10.1158/1535-7163.MCT-12-0737)
54. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J et al. 2014 Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Molecular Systems Biology 10 728. (doi:10.1002/msb.20134892)
55. Yoshioka S, King ML, Ran S, Okuda H, MacLean JA II, McAsey ME, Sugino N, Brard L, WatabeK&HayashiK2012WNT7Aregulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway. Molecular Cancer Research 10 469-482. (doi:10.1158/1541-7786.MCR-11-0177)
56. Yuneva M, Zamboni N, Oefner P, Sachidanandam R & Lazebnik Y 2007 Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. Journal of Cell Biology 178 93-105. (doi:10.1083/jcb.200703099)